



Date: 12.08.2019

The Manager (Department of Corporate Services)  
Bombay Stock Exchange Limited (BSE)  
P.J. Towers, 25<sup>th</sup> Floor, Dalal Street, Fort  
Mumbai- 400001

Scrip Code: 526707

The Manager (Listing Department)  
National Stock Exchange of India Limited (NSE)  
Exchange Plaza, Bandra Kurla Complex  
Bandra (East), Mumbai- 400051

Scrip Code: ALCHEM

**Sub: Outcome of Board Meeting**

Dear Sir/Madam,

Pursuant to provisions of regulation 30 and 33 and any other applicable provisions, if any of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (hereinafter refer as "SEBI Listing Regulations") please note that the Board of Directors of the Company in its meeting held on today i.e. 12<sup>th</sup> August, 2019, have inter— alia considered, approved and taken on record the followings:—


1. Unaudited Financial Results (Standalone/Consolidated) of the company for the quarter ended on 30<sup>th</sup> June, 2019. A copy of the same as per regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached as **Annexure -1**.
2. Limited Review Report (Standalone/Consolidated) on the Unaudited Financial Results for the quarter ended on 30<sup>th</sup> June, 2019 as obtained from Statutory Auditors. A copy of the same is attached as **Annexure -2**.

We further wish to inform you that the Board Meeting held today Commenced at 15:30 hours and Concluded at 19:45 hours.

You are requested to take the above information in your records & acknowledge the same.

Thanking you,  
Yours Sincerely,

For Alchemist Limited

  
Sunil Jain  
Company Secretary



Encl: As above

**ALCHEMIST LTD.**

CIN : L72200DL1988PLC192643

Regd. & Head Office : Alchemist House, Building No. 23, Nehru Place, New Delhi - 110019 Tel. : +91 - 40600800, Fax : +91-40600888  
Chd. Office : Plot No. F5, Rajiv Gandhi IT Park, Chandigarh - 160 101 Tel. : +91-172-4266666, Fax: +91-172-4266602  
E-mail : investors@alchemist.co.in Website : www.alchemist.co.in

**ALCHEMIST LIMITED**

**REGD.OFFICE : 23 NEHRU PLACE, NEW DELHI-110 019**

CIN NO.:L72200DL1988PLC192643. Tel No.: (91-11) 40600800. Fax: (91-11) 40600888. E-mail: info@alchemist.co.in. Website: www.alchemist.co.in

**PART I: STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30<sup>TH</sup> JUNE, 2019**

| Sr. No. | Particulars   | (₹ in Lakhs except EPS data) |                              |                           |                       |
|---------|---|------------------------------|------------------------------|---------------------------|-----------------------|
|         |   | STANDALONE                   |                              |                           |                       |
|         |   | Quarter Ended                |                              | Year Ended                |                       |
|         |   | 30.06.2019<br>(Unaudited)    | 31.03.2019<br>(Refer Note 2) | 30.06.2018<br>(Unaudited) | 31.03.19<br>(Audited) |
| 1       | Net Sales (Net of Excise Duty) / Incomes from Operations                      | 585.68                       | 571.69                       | 865.80                    | 2673.60               |
| 2       | Other Income  | 0.87                         | 9.14                         | 0.64                      | 92.18                 |
| 3       | Total Revenue (1+2)   | <b>586.54</b>                | <b>580.83</b>                | <b>866.44</b>             | <b>2765.78</b>        |
| 4       | Expenditure   |                              |                              |                           |                       |
|         | a) Consumption of Raw Material & Others                                       | 188.72                       | 229.17                       | 272.18                    | 847.60                |
|         | b) Purchase of stock in trade   | 178.05                       | 247.54                       | 310.88                    | 1109.44               |
|         | c) (Increase)/decrease in stock in trade, finished goods and work in progress | 10.00                        | (3.19)                       | 13.08                     | 24.24                 |
|         | d) Employees benefit expenses   | 157.61                       | 161.50                       | 204.81                    | 738.35                |
|         | e) Finance costs  | 12.02                        | 29.88                        | 34.27                     | 136.91                |
|         | f) Depreciation & Amortisation  | 167.42                       | 165.61                       | 175.71                    | 690.01                |
|         | g) Other Expenditure  |                              |                              |                           |                       |
|         | (i) Foreign Exchange (Gain)/Loss  | 0.00                         | 0.00                         | (1851.16)                 | 0.00                  |
|         | (ii) Provision for Expected Credit Loss                                       | 0.00                         | (0.00)                       | 0.00                      | 4644.28               |
|         | (ii) Other Expenditure other than (i) above                                   | 145.86                       | 184.79                       | 152.63                    | 634.92                |
|         | Total Expenses  | <b>859.68</b>                | <b>1015.30</b>               | <b>(687.60)</b>           | <b>8825.75</b>        |
| 5       | Profit before Exceptional & Extraordinary Items (3-4)                         | <b>(273.14)</b>              | <b>(434.47)</b>              | <b>1554.04</b>            | <b>(6059.97)</b>      |
| 6       | Exceptional Items   | -                            | -                            | -                         | -                     |
| 7       | Profit Before Tax (5-6-7)   | <b>(273.14)</b>              | <b>(434.47)</b>              | <b>1554.04</b>            | <b>(6059.97)</b>      |
| 8       | <b>Tax Expenses</b>   |                              |                              |                           |                       |
|         | a) Current Tax  | -                            | -                            | -                         | -                     |
|         | b) Deferred Tax   | 19.54                        | (1177.36)                    | (18.12)                   | (1096.21)             |
| 9       | <b>Profit(+)/ Loss(-) for the period (8-9)</b>                                | <b>(292.68)</b>              | <b>742.89</b>                | <b>1572.16</b>            | <b>(4963.76)</b>      |
| 10      | <b>Other Comprehensive Income</b>   |                              |                              |                           |                       |
|         | Items that will not be reclassified to profit or loss                         |                              |                              |                           |                       |
|         | Re-measurement of the net defined benefit plans                               | 0.00                         | 4.07                         | (20.52)                   | (14.84)               |
|         | Tax on above  | 0.00                         | (1.06)                       | 5.34                      | 3.86                  |
| 11      | <b>Total Other comprehensive Income, net of tax</b>                           | <b>0.00</b>                  | <b>3.01</b>                  | <b>(15.19)</b>            | <b>(10.98)</b>        |
| 12      | <b>Total comprehensive Income, for the period</b>                             | <b>(292.68)</b>              | <b>745.90</b>                | <b>1556.97</b>            | <b>(4974.74)</b>      |
| 13      | <b>Paid up equity share capital</b>   | <b>1355.98</b>               | <b>1355.98</b>               | <b>1355.98</b>            | <b>1355.98</b>        |
|         | (Face Value of ₹10/- each per share)  |                              |                              |                           |                       |
| 14      | <b>Basic and diluted Earning Per Share (EPS) after Extra Ordinary Items</b>   |                              |                              |                           |                       |
|         | - Basic   | (2.16)                       | 5.48                         | 11.59                     | (36.61)               |
|         | - Diluted   | (2.16)                       | 5.48                         | 11.59                     | (36.61)               |




| PART II: SEGMENT INFORMATION FOR THE QUARTER AND YEAR ENDED 30.06.2019 |  |                 |                 |                 |                  |
|--|--|-----------------|-----------------|-----------------|------------------|
| (₹ in Lakhs)   |  |                 |                 |                 |                  |
| S.No.  | Particulars  | STANDALONE      |                 |                 |                  |
|  |  | Quarter Ended   |                 |                 | Year Ended       |
|  |  | 30.06.2019      | 31.03.2019      | 30.06.2018      | 31.03.19         |
|  |  | (Unaudited)     | (Refer Note 2)  | (Unaudited)     | (Audited)        |
| <b>1</b>   | <b>Segment Revenue (Net)</b>                         |                 |                 |                 |                  |
|  | a) Pharma, Chemical & Minerals                       | 319.13          | 304.09          | 524.60          | 1551.58          |
|  | b) Agri Business                                     | 266.54          | 267.61          | 341.21          | 1122.03          |
|  | <b>Sub-Total</b>                                     | <b>585.68</b>   | <b>571.69</b>   | <b>865.80</b>   | <b>2673.60</b>   |
|  | Less Inter Segment Revenue                           | -               | -               |                 |                  |
|  | <b>Net Sales/Incomes</b>                             | <b>585.68</b>   | <b>571.69</b>   | <b>865.80</b>   | <b>2673.60</b>   |
| <b>2</b>   | <b>Segment Results</b>                               |                 |                 |                 |                  |
|  | Profit/(Loss) before tax and interest from segments) |                 |                 |                 |                  |
|  | a) Pharma, Chemical & Minerals                       | (174.56)        | (477.77)        | 1685.05         | (5772.25)        |
|  | b) Agri Business                                     | (87.43)         | 64.04           | (97.37)         | (242.99)         |
|  | <b>Total</b>   | <b>(261.99)</b> | <b>(413.73)</b> | <b>1587.68</b>  | <b>(6015.24)</b> |
|  | Less: Financial Charges                              | 12.02           | 29.88           | 34.27           | 136.91           |
|  | Add: Other Incomes                                   | 0.87            | 9.14            | 0.64            | 92.18            |
|  | Less: Exceptional Item                               | -               | -               | 0.00            | 0.00             |
|  | <b>Total Profit before Tax</b>                       | <b>(273.14)</b> | <b>(434.47)</b> | <b>1554.04</b>  | <b>(6059.97)</b> |
|  | Current and Deferred Tax                             | 19.54           | (1177.36)       | (18.12)         | (1096.21)        |
|  | <b>Total Profit after Tax</b>                        | <b>(292.68)</b> | <b>742.89</b>   | <b>1572.16</b>  | <b>(4963.76)</b> |
| <b>3</b>   | <b>Segment Assets</b>                                |                 |                 |                 |                  |
|  | a) Pharma, Chemical & Minerals                       | 43868.13        | 43679.46        | 51327.17        | 43679.46         |
|  | b) Agri Business                                     | 965.80          | 959.06          | 991.33          | 959.06           |
|  | <b>Total Assets</b>                                  | <b>44833.94</b> | <b>44638.51</b> | <b>52318.49</b> | <b>44638.51</b>  |
| <b>4</b>   | <b>Segment Liabilities</b>                           |                 |                 |                 |                  |
|  | a) Pharma, Chemical & Minerals                       | 14871.22        | 14605.91        | 14738.56        | 14605.91         |
|  | b) Agri Business                                     | 151.44          | 159.11          | 165.93          | 159.11           |
|  | <b>Total Liabilities</b>                             | <b>15022.66</b> | <b>14765.01</b> | <b>14904.50</b> | <b>14765.01</b>  |
| <b>5</b>   | <b>Capital Employed</b>                              |                 |                 |                 |                  |
|  | (Segment assets-Segment Liabilities)                 |                 |                 |                 |                  |
|  | a) Pharma, Chemical & Minerals                       | 28996.91        | 29073.55        | 36588.60        | 29073.55         |
|  | b) Agri Business                                     | 814.36          | 799.95          | 825.38          | 799.95           |
|  | <b>Total</b>   | <b>29811.28</b> | <b>29873.50</b> | <b>37413.99</b> | <b>29873.50</b>  |

**NOTES :**

- 1) The above standalone financial results, as reviewed by Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 12<sup>th</sup> August, 2019. The Statutory Auditors have expressed modified opinion on these results.
- 2) Figures for the quarter ended 31<sup>st</sup> March 2019 are the balancing figures between audited figures for the full financial year and the reviewed year to date figures upto the third quarter of the financial year.
- 3) The Company extends credit from time to time as per market practices. In respect of export receivables amounting to ₹ 46,442.79 Lakhs, credit was extended for export sales in the normal course of the business, however it apparently got stuck. Though the Company is regularly following up on the same, has initiated legal recourse and is hopeful of recovering such amount, considering the principal of conservatism, the Company had made a provision for expected credit loss @ 10% of the outstanding export receivables amounting to ₹ 4,644.28 Lakhs and has not recognised unrealised foreign exchange gain/loss on such export receivable and related trade payable during the financial year 2018-19. Hence forth, the Company has not accounted for the unrealised foreign exchange loss on such export receivable and related trade payables and the same will only be accounted for on actual realisation/payment.
- 4) The accumulated losses of the Company had exceeded its net worth. The company's operations were adversely affected in earlier financial years due to sluggish market demand, working capital getting stuck in trade receivables and loss making manufacturing activity of the pharmaceutical unit. The Company has initiated legal recourse against the defaulting customers and is regularly following up on the same and the Company during the last year has even closed down its loss making pharmaceutical manufacturing. The units of the company now continue to operate at satisfactory capacity utilization levels and are generating positive Earnings before Interest Depreciation Tax and Amortization (EBIDTA). With strong management focus on strategic initiatives for cost rationalization, optimum product mix and efficient plant operations, the management believes that accumulated losses would reasonably be paired, in due course. The financial statements, as such have been prepared on a going concern basis.
- 5) On 30<sup>th</sup> March, 2019 MCA notified Ind AS 116 Leases and it replaces Ind AS 17 leases, including appendices thereto. Ind AS 116 is effective for annual periods beginning on or after April 1, 2019. Ind AS 116 sets out the principles for recognition, measurement, presentation and disclosures of leases and requires lessees to account for all leases under a single on balance sheet model similar to the accounting for finance lease under Ind AS 17.  
The Company has adopted Ind AS 116 effective annual reporting period beginning April 1, 2019 and applied the standard to its leases, retrospectively with the cumulative effect of initially applying the standard, recognised on the date of initial application (April 1, 2019). Accordingly, the Company has not restated comparative information, instead, the cumulative effect of initially applying the standard, if any, has been recognised as an adjustment to the opening balance of retained earnings as on April 1, 2019. The adaptation of Ind AS 116 has not materially effected the Company.
- 6) As required by Ind As 19 "Employee benefits", the Company has not made provision for Gratuity. The same will be provided at the end of year.
- 7) The figures for the previous period have been regrouped/ reclassified, wherever necessary to confirm to the current period's presentation.

*for and behalf of the Board of Alchemist Limited*

**Place:** New Delhi  
**Date:** 12<sup>th</sup> August, 2019

  
**Bikram Bhattacharya**  
Whole Time Director



**ALCHEMIST LIMITED**

**REGD.OFFICE : 23 NEHRU PLACE, NEW DELHI-110 019**

CIN NO.:L72200DL1988PLC192643. Tel No.: (91-11) 40600800. Fax: (91-11) 40600888. E-mail: info@alchemist.co.in. Website: www.alchemist.co.in

**PART I: STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30<sup>TH</sup> JUNE, 2019**

| Sr. No. | Particulars   | (₹ in Lakhs except EPS data) |                              |                           |                       |
|---------|---|------------------------------|------------------------------|---------------------------|-----------------------|
|         |   | CONSOLIDATED                 |                              |                           |                       |
|         |   | Quarter Ended                |                              | Year Ended                |                       |
|         |   | 30.06.2019<br>(Unaudited)    | 31.03.2019<br>(Refer Note 2) | 30.06.2018<br>(Unaudited) | 31.03.19<br>(Audited) |
| 1       | Net Sales (Net of Excise Duty) / Incomes from Operations                      | 585.68                       | 571.69                       | 865.80                    | 2673.60               |
| 2       | Other Income  | 0.87                         | 9.14                         | 0.64                      | 92.18                 |
| 3       | Total Revenue (1+2)   | <b>586.54</b>                | <b>580.83</b>                | <b>866.44</b>             | <b>2765.78</b>        |
| 4       | Expenditure   |                              |                              |                           |                       |
|         | a) Consumption of Raw Material & Others                                       | 188.72                       | 229.17                       | 272.18                    | 847.60                |
|         | b) Purchase of stock in trade   | 178.05                       | 247.54                       | 310.88                    | 1109.44               |
|         | c) (Increase)/decrease in stock in trade, finished goods and work in progress | 10.00                        | (3.19)                       | 13.08                     | 24.24                 |
|         | d) Employees benefit expenses   | 157.61                       | 161.50                       | 204.81                    | 738.35                |
|         | e) Finance costs  | 12.02                        | 29.88                        | 34.27                     | 136.91                |
|         | f) Depreciation & Amortisation  | 167.42                       | 165.61                       | 175.71                    | 690.01                |
|         | g) Other Expenditure  |                              |                              |                           |                       |
|         | (i) Foreign Exchange (Gain)/Loss  | 0.00                         | 0.00                         | (1851.16)                 | 0.00                  |
|         | (ii) Provision for Expected Credit Loss                                       | 0.00                         | (0.00)                       | 0.00                      | 4644.28               |
|         | (ii) Other Expenditure other than (i) above                                   | 145.86                       | 185.03                       | 152.65                    | 635.18                |
|         | Total Expenses  | <b>859.68</b>                | <b>1015.55</b>               | <b>(687.58)</b>           | <b>8826.01</b>        |
| 5       | Profit before Exceptional & Extraordinary Items (3-4)                         | <b>(273.14)</b>              | <b>(434.71)</b>              | <b>1554.02</b>            | <b>(6060.23)</b>      |
| 6       | Exceptional Items   | -                            | -                            | -                         | -                     |
| 7       | Profit Before Tax (5-6-7)   | <b>(273.14)</b>              | <b>(434.71)</b>              | <b>1554.02</b>            | <b>(6060.23)</b>      |
| 8       | Tax Expenses  |                              |                              |                           |                       |
|         | a) Current Tax  | -                            | -                            | -                         | -                     |
|         | b) Deferred Tax   | 19.54                        | (1177.36)                    | (18.12)                   | (1096.21)             |
| 9       | Profit(+)/ Loss(-) for the period (8-9)                                       | <b>(292.68)</b>              | <b>742.64</b>                | <b>1572.14</b>            | <b>(4964.02)</b>      |
| 10      | Other Comprehensive Income  |                              |                              |                           |                       |
|         | Items that will not be reclassified to profit or loss                         |                              |                              |                           |                       |
|         | Re-measurement of the net defined benefit plans                               | 0.00                         | 4.07                         | (20.52)                   | (14.84)               |
|         | Tax on above  | 0.00                         | (1.06)                       | 5.34                      | 3.86                  |
| 11      | Total Other comprehensive Income, net of tax                                  | <b>0.00</b>                  | <b>3.01</b>                  | <b>(15.19)</b>            | <b>(10.98)</b>        |
| 12      | Total comprehensive Income, for the period                                    | <b>(292.68)</b>              | <b>745.65</b>                | <b>1556.95</b>            | <b>(4975.00)</b>      |
| 13      | Loss for the Year Attributed to   |                              |                              |                           |                       |
|         | Owners of The Parent  | (292.68)                     | 742.76                       | 1,572.15                  | (4,963.90)            |
|         | Non-Controlling Interests   | -                            | (0.12)                       | (0.01)                    | (0.13)                |
| 14      | Other Comprehensive Income for the Year Attributable to                       |                              |                              |                           |                       |
|         | Owners of the Parent  | -                            | 3.01                         | (15.19)                   | (10.98)               |
|         | Non-Controlling Interests   | -                            | -                            | -                         | -                     |
| 15      | Paid up equity share capital<br>(Face Value of ₹10/- each per share)          | <b>1355.98</b>               | <b>1355.98</b>               | <b>1355.98</b>            | <b>1355.98</b>        |
| 16      | Basic and diluted Earning Per Share (EPS) after Extra Ordinary Items          |                              |                              |                           |                       |
|         | - Basic   | (2.16)                       | 5.48                         | 11.59                     | (36.61)               |
|         | - Diluted   | (2.16)                       | 5.48                         | 11.59                     | (36.61)               |

**PART II: SEGMENT INFORMATION FOR THE QUARTER AND YEAR ENDED 30.06.2019**

(₹ in Lakhs)

| Sr. No.  | Particulars  | CONSOLIDATED    |                 |                 |                  |
|----------|--|-----------------|-----------------|-----------------|------------------|
|          |  | Quarter Ended   |                 |                 | Year Ended       |
|          |  | 30.06.2019      | 31.03.2019      | 30.06.2018      | 31.03.19         |
|          |  | (Unaudited)     | (Refer Note 2)  | (Unaudited)     | (Audited)        |
| <b>1</b> | <b>Segment Revenue (Net)</b>                         |                 |                 |                 |                  |
|          | a) Pharma, Chemical & Minerals                       | 319.13          | 304.09          | 524.60          | 1551.58          |
|          | b) Agri Business                                     | 266.54          | 267.61          | 341.21          | 1122.03          |
|          | <b>Sub-Total</b>                                     | <b>585.68</b>   | <b>571.69</b>   | <b>865.80</b>   | <b>2673.60</b>   |
|          | Less Inter Segment Revenue                           | -               | -               | -               | -                |
|          | <b>Net Sales/Incomes</b>                             | <b>585.68</b>   | <b>571.69</b>   | <b>865.80</b>   | <b>2673.60</b>   |
| <b>2</b> | <b>Segment Results</b>                               |                 |                 |                 |                  |
|          | Profit/(Loss) before tax and interest from segments) |                 |                 |                 |                  |
|          | a) Pharma, Chemical & Minerals                       | (174.56)        | (477.77)        | 1685.05         | (5772.25)        |
|          | b) Agri Business                                     | (87.43)         | 64.04           | (97.37)         | (242.99)         |
|          | <b>Total</b>   | <b>(261.99)</b> | <b>(413.73)</b> | <b>1587.68</b>  | <b>(6015.24)</b> |
|          | Less: Financial Charges                              | 12.02           | 29.88           | 34.27           | 136.91           |
|          | Add: Other Incomes                                   | 0.87            | 9.14            | 0.64            | 92.18            |
|          | Less: Exceptional Item                               | -               | -               | -               | -                |
|          | Less: Unallocated expense of Subsidiary              |                 | 0.24            | 0.03            | 0.26             |
|          | <b>Total Profit before Tax</b>                       | <b>(273.14)</b> | <b>(434.71)</b> | <b>1554.02</b>  | <b>(6060.23)</b> |
|          | Current and Deferred Tax                             | 19.54           | (1177.36)       | (18.12)         | (1096.21)        |
|          | <b>Total Profit after Tax</b>                        | <b>(292.68)</b> | <b>742.64</b>   | <b>1572.14</b>  | <b>(4964.02)</b> |
| <b>3</b> | <b>Segment Assets</b>                                |                 |                 |                 |                  |
|          | a) Pharma, Chemical & Minerals                       | 43868.13        | 43679.46        | 51327.17        | 43679.46         |
|          | b) Agri Business                                     | 965.80          | 959.06          | 991.33          | 959.06           |
|          | <b>Total Assets</b>                                  | <b>44833.94</b> | <b>44638.51</b> | <b>52318.49</b> | <b>44638.51</b>  |
| <b>4</b> | <b>Segment Liabilities</b>                           |                 |                 |                 |                  |
|          | a) Pharma, Chemical & Minerals                       | 14871.22        | 14605.91        | 14738.56        | 14605.91         |
|          | b) Agri Business                                     | 151.44          | 159.11          | 165.93          | 159.11           |
|          | <b>Total Liabilities</b>                             | <b>15022.66</b> | <b>14765.01</b> | <b>14904.50</b> | <b>14765.01</b>  |
| <b>5</b> | <b>Capital Employed</b>                              |                 |                 |                 |                  |
|          | (Segment assets-Segment Liabilities)                 |                 |                 |                 |                  |
|          | a) Pharma, Chemical & Minerals                       | 28996.91        | 29073.55        | 36588.60        | 29073.55         |
|          | b) Agri Business                                     | 814.36          | 799.95          | 825.38          | 799.95           |
|          | <b>Total</b>   | <b>29811.28</b> | <b>29873.50</b> | <b>37413.99</b> | <b>29873.50</b>  |




**NOTES :**

- 1) The above consolidated financial results, as reviewed by Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 12<sup>th</sup> August, 2019. The Statutory Auditors have expressed modified opinion on these results.
- 2) Figures for the quarter ended 31<sup>st</sup> March 2019 are the balancing figures between audited figures for the full financial year and the reviewed year to date figures upto the third quarter of the financial year.
- 3) In respect of Alchemist Limited, the Parent extends credit from time to time as per market practices. In respect of export receivables amounting to ₹ 46,442.79 Lakhs, credit was extended for export sales in the normal course of the business, however it apparently got stuck. Though the Parent is regularly following up on the same, has initiated legal recourse and is hopeful of recovering such amount, considering the principal of conservatism, the Parent had made a provision for expected credit loss @ 10% of the outstanding export receivables amounting to ₹ 4,644.28 Lakhs and has not recognised unrealised foreign exchange gain/ loss on such export receivable and related trade payable during the financial year 2018-19. Hence forth, the Company has not accounted for the unrealised foreign exchange loss on such export receivable and related trade payables and the same will only be accounted for on actual realisation/ payment.
- 4) In respect of Alchemist Limited, the accumulated losses of the Parent had exceeded its net worth. The Parent's operations were adversely affected in earlier financial years due to sluggish market demand, working capital getting stuck in trade receivables and loss making manufacturing activity of the pharmaceutical unit. The Parent has initiated legal recourse against the defaulting customers and is regularly following up on the same and the Parent during the last year has even closed down its loss making pharmaceutical manufacturing. The units of the Parent now continue to operate at satisfactory capacity utilization levels and are generating positive Earnings before Interest Depreciation Tax and Amortization (EBIDTA). With strong management focus on strategic initiatives for cost rationalization, optimum product mix and efficient plant operations, the management believes that accumulated losses would reasonably be paired, in due course. The financial statements, as such have been prepared on a going concern basis
- 5) On 30<sup>th</sup> March, 2019 MCA notified Ind AS 116 Leases and it replaces Ind AS 17 leases, including appendices thereto. Ind AS 116 is effective for annual periods beginning on or after April 1, 2019. Ind AS 116 sets out the principles for recognition, measurement, presentation and disclosures of leases and requires lessees to account for all leases under a single on balance sheet model similar to the accounting for finance lease under Ind AS 17.  
The Group has adopted Ind AS 116 effective annual reporting period beginning April 1, 2019 and applied the standard to its leases, retrospectively with the cumulative effect of initially applying the standard, recognised on the date of initial application (April 1, 2019). Accordingly, the Company has not restated comparative information, instead, the cumulative effect of initially applying the standard, if any, has been recognised as an adjustment to the opening balance of retained earnings as on April 1, 2019. The adaptation of Ind AS 116 has not materially effected the Group.
- 6) As required by Ind As 19 "Employee benefits", the Parent has not made provision for Gratuity. The same will be provided at the end of year.
- 7) The figures for the previous period have been regrouped/ reclassified, wherever necessary to confirm to the current period's presentation.

*for and behalf of the Board of Alchemist Limited*

Place: New Delhi  
Date: 12<sup>th</sup> August, 2019

  
**Bikram Bhattacharya**  
Whole Time Director



**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Alchemist Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).**

**To**  
**The Board of Directors**  
**Alchemist Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of **Alchemist Limited** ("the Company") for the quarter ended 30<sup>th</sup> June, 2019, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the Securities and Exchange Board of India ("SEBI") from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 for 'Interim Financial Reporting' prescribed under Section 133 of Companies Act, 2013, SEBI Circular CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 (herein referred to as "the SEBI Circular") and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for the financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters and might be identified in an Audit. Accordingly, we do not express an audit opinion.
4. Attention is invited to note no. 3 of the accompanying statement which states that "The Company extends credit from time to time as per market practices. In respect of export receivables amounting to ₹ 46,442.79 Lakhs, credit was extended for export sales in the normal course of the business, however it apparently got stuck. Though the Company is regularly following up on the same, has initiated legal recourse and is hopeful of recovering such amount,





considering the principal of conservatism, the Company had made a provision for expected credit loss @ 10% of the outstanding export receivables amounting to ₹ 4,644.28 Lakhs and has not recognised unrealised foreign exchange gain/loss on such export receivable and related trade payable during the financial year 2018-19. Hence forth, the Company has not accounted for the unrealised foreign exchange loss on such export receivable and related trade payables and the same will only be accounted for on actual realisation/ payment".

***Such export receivables are outstanding for more than three years as at the quarter end date, provision @ 10% is made against such doubtful trade receivables. Since the actual realisation of such doubtful export receivable cannot be ascertained, we are unable to comment on the adequacy of the provision of excepted credit loss made by the Company. The loss to that extent is under stated, the effect however could not be quantified.***

***Though, the Company admits that the export receivable is doubtful of recovery and has made partial provision on such export receivable, still such export receivable and related trade payable stand in the books, hence require recognition of unrealised foreign exchange gain/ loss as per the provisions of Ind AS 21, 'The Effects of Changes in Foreign Exchange Rates'. Accordingly, the loss is understated by ₹ 257.19 Lakhs for the quarter ended 30<sup>th</sup> June, 2019.***

5. Attention is invited to note no. 6 of the accompanying statement which states that "As required by Ind AS 19 "Employee benefits", the Company has not made provision for Gratuity. The same will be provided at the end of year." ***Consequently, loss is understated to that extent, in the absence of any information the effect is presently not ascertainable.***
6. Based on our review conducted as stated in paragraph 3 above, ***subject to the impact of our observation in paragraphs 4 and 5 above***, nothing else has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standards and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. Attention is invited to note no.4 of the accompanying statement which states that "The accumulated losses of the Company had exceeded its net worth. The company's operations were adversely affected in earlier financial years due to sluggish market demand, working capital getting stuck in trade receivables and loss making manufacturing activity of the pharmaceutical unit. The Company has initiated legal recourse against the defaulting customers and is regularly following up on the same and the Company during the last year has even closed down its loss making pharmaceutical manufacturing. The units of the company



now continue to operate at satisfactory capacity utilization levels and are generating positive Earnings before Interest Depreciation Tax and Amortization (EBIDTA). With strong management focus on strategic initiatives for cost rationalization, optimum product mix and efficient plant operations, the management believes that accumulated losses would reasonably be paired, in due course. The standalone financial results, as such have been prepared on a going concern basis".

Our review report is not qualified in respect of the matter as stated in the above paragraphs.

*for Anu and Associates*  
**Chartered Accountants**  
**Firm registration Number 019624N**

*Parveen*  
**CA. Parveen Kumar**  
*Partner*  
Membership Number 531655  
**UDIN: 19531655AAAAAW2924**



**Place:** New Delhi  
**Date:** 12<sup>th</sup> August, 2019



**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Alchemist Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).**

**To**  
**The Board of Directors**  
**Alchemist Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ("the Statement") of **Alchemist Limited** ("the Parent"), its subsidiary and associate (the Parent, its subsidiary and associate together referred to as "the Group") (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30<sup>th</sup> June, 2019, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by Stock and Exchange Board of India (SEBI) from time to time.
2. The statement, which is the responsibility of the Parent's Management and been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 for 'Interim Financial Reporting' prescribed under Section 133 of Companies Act, 2013, SEBI Circular CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 (herein referred to as "the SEBI Circular") and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for the financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters and might be identified in any Audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29<sup>th</sup> March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.

4. *It has been explained to us that the financial statements of the two associates, ROC Foods Limited and Alchemist Medisphere Limited are still*





**under compilation and two subsidiaries viz. Alchemist Infrastructure Private Limited and Alchemist Hospitality Group Limited are under strike-off. Therefore, the same are not forming part of the consolidated financial results.**

5. Attention is invited to note no. 3 of the accompanying statement which states that "In respect of Alchemist Limited, the Parent extends credit from time to time as per market practices. In respect of export receivables amounting to ₹ 46,442.79 Lakhs, credit was extended for export sales in the normal course of the business, however it apparently got stuck. Though the Parent is regularly following up on the same, has initiated legal recourse and is hopeful of recovering such amount, considering the principal of conservatism, the Parent had made a provision for expected credit loss @ 10% of the outstanding export receivables amounting to ₹ 4,644.28 Lakhs and has not recognised unrealised foreign exchange gain/ loss on such export receivable and related trade payable during the financial year 2018-19. Hence forth, the Company has not accounted for the unrealised foreign exchange loss on such export receivable and related trade payables and the same will only be accounted for on actual realisation/ payment".

**Such export receivables are outstanding for more than three years as at the quarter end date, provision @ 10% is made against such doubtful trade receivables. Since the actual realisation of such doubtful export receivable cannot be ascertained, we are unable to comment on the adequacy of the provision of expected credit loss made by the Parent Company. The loss to that extent is under stated, the effect however could not be quantified.**

**Though, the Parent admits that the export receivable is doubtful of recovery and has made partial provision on such export receivable, still such export receivable and related trade payable stand in the books, hence require recognition of unrealised foreign exchange gain/ loss as per the provisions of Ind AS 21, 'The Effects of Changes in Foreign Exchange Rates'. Accordingly, the loss is understated by ₹ 257.19 Lakhs for the quarter ended 30<sup>th</sup> June, 2019.**

6. Attention is invited to note no. 6 of the accompanying statement which states that "As required by Ind AS 19 "Employee benefits", the Parent has not made provision for Gratuity. The same will be provided at the end of year." **Consequently, loss is understated to that extent, in the absence of any information the effect is presently not ascertainable.**
7. Based on our review conducted as stated in paragraph 3 above, **subject to the impact of our observation in paragraphs 4 to 6 above**, nothing else has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standards and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.





8. Attention is invited to note no. 5 of the accompanying statement which states that "In respect of Alchemist Limited, the accumulated losses of the Parent had exceeded its net worth. The Parent's operations were adversely affected in earlier financial years due to sluggish market demand, working capital getting stuck in trade receivables and loss making manufacturing activity of the pharmaceutical unit. The Parent has initiated legal recourse against the defaulting customers and is regularly following up on the same and the Parent during the last year has even closed down its loss making pharmaceutical manufacturing. The units of the Parent now continue to operate at satisfactory capacity utilization levels and are generating positive Earnings before Interest Depreciation Tax and Amortization (EBIDTA). With strong management focus on strategic initiatives for cost rationalization, optimum product mix and efficient plant operations, the management believes that accumulated losses would reasonably be paired, in due course. The financial statements, as such have been prepared on a going concern basis".

Our review report is not qualified in respect of the matter as stated in the above paragraphs.

9. We did not review the financial statements of Alchemist Healthcare Limited included in the consolidated financial results for the year ended 30<sup>th</sup> June, 2019. These financial statements have been reviewed by other auditors whose reports have been furnished to us, and our opinion on the financial results for the year ending 30<sup>th</sup> June, 2019, to the extent they have been derived from such financial statements is based solely on the reports of such other auditors.

Our review report is not qualified in respect of the matter as stated in the above paragraphs.

for **Anu and Associates**  
Chartered Accountants  
Firm registration Number 019624N

  
**CA. Parveen Kumar**

Partner

Membership Number 531655

UDIN: 19531655AAAAAX6077



**Place:** New Delhi

**Date:** 12<sup>th</sup> August, 2019